Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Study of LEE011 Plus Everolimus in Patients With Metastatic Pancreatic Adenocarcinoma Refractory to Chemotherapy

NCT02985125 is registered in ClinicalTrials.gov with Georgetown University as lead sponsor.

NCT NCT02985125
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02985125 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Study of LEE011 Plus Everolimus in Patients With Metastatic Pancreatic Adenocarcinoma Refractory to Chemotherapy
Lead sponsor
Georgetown University
Phase
Phase 1/2
Overall status
Completed
Start date
May 4, 2017
Completion date
September 28, 2020
Enrollment
12 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic pancreatic adenocarcinoma